EZH2 and myelodysplastic syndrome: In contrast, although in our cohort EZH2 mutations were more common in high-risk patients and had no prognostic value, a previous study identified a group of lower-risk MDS patients with EZH2 mutations and worse-than-expected prognosis [24].